key topics covered during the meeting

Look at our shared success as ONE team in CML to date!

How can we leverage the latest data and insights in CML for optimal patient management?

How can we collaborate with multidisciplinary teams to optimise care?

What practical lessons can we learn from our collective knowledge and experience?

Download the agenda Here

OVERVIEW OF FULL AGENDA – DAY 1

Time
Session
13.30–14.00
ARRIVALS AND COFFEE
14:00–14:20
WELCOME AND INTRODUCTION
  • Incyte: Pivotal science – Jonathan Dickinson
  • We are ONE: Celebrating our shared successes in CML ‒ Gianantonio Rosti & Valentín García-Gutiérrez
14:20–15:20
TREATMENT OPTIONS AFTER ONE 2G TKI: UPDATES IN CML
  • Recent highlights and clinical updates in CML ‒ Jane Apperley
  • Case studies: How I select a TKI and optimise dose in patients who have failed a 2G TKI ‒ Elias Jabbour
  • Q&A
15:20–16:20
ONE SHARED EXPERIENCE: REAL-WORLD DATA FROM REGISTRIES EXPLORING TKI USE IN CML
  • A retrospective analysis of patients treated with ponatinib from Italian registries ‒ Massimo Breccia
  • A 5-year analysis of ponatinib treatment from a Belgian registry ‒ Dominiek Mazure
  • TOPASE, an observational study of patients treated with ponatinib from 42 CML centres in France ‒ Emilie Cayssials
  • Q&A
16:20–16:35
COFFEE BREAK
16:35–17:35
ONE GOAL: OVERCOMING TREATMENT CHALLENGES IN CML

Discussing patient scenarios submitted by your peers and sharing experiences to overcome treatment challenges today ‒ Gianantonio Rosti & Valentín García-Gutiérrez

17:35–17:40
CLOSE DAY 1

OVERVIEW OF FULL AGENDA – DAY 2

Time
Session
08.30–09.00
ARRIVALS AND COFFEE
09.00–09.05
WELCOME BACK ‒ Gianantonio Rosti & Valentín García-Gutiérrez
  • Beyond the clinic: A patient’s perspective on living with CML
09:05–09:50
MONITORING RESPONSE IN PATIENTS WITH CML: ONE OPPORTUNITY TO SECURE LASTING OUTCOMES
  • BCR::ABL1 transcript monitoring to enable rapid decision making: Milestone measurements versus kinetics ‒ Simona Soverini
  • Case studies: My experience treating CML patients with a TKI that has pan-mutational coverage after failure of a 2G TKI ‒ Dragana Milojkovic
  • Q&A
09:50–10:55
ONE TEAM: WORKING TOGETHER TO OPTIMISE CARE FOR PATIENTS WITH CML
  • Meet the multidisciplinary experts ‒ Paolo Tarsia (pulmonologist); Rudolf Kirchmair (cardiologist); Pietro Sollena (dermatologist)
  • Q&A
10:55–11:10
COFFEE BREAK
11:10–12:10
ONE TEAM: EXPLORING THE PATIENT JOURNEY IN CML THROUGH THE MDT
  • Your opportunity to engage with key members of the MDT and overcome challenges in patient management ‒ Paolo Tarsia (pulmonologist); Rudolf Kirchmair (cardiologist); Pietro Sollena (dermatologist)
12:10–12:20
MEETING CLOSE